Evidence map›Paper›PMID 40628889›Full record

ArticleScientific reports2025

Clinicopathological features of type 1 autoimmune pancreatitis without elevated serum IgG4 level.

Yumiko Yamashita, Yasutaka Ishii, Keiji Hanada, Tamito Sasaki, Yoshifumi Fujimoto, Atsushi Yamaguchi, Ken Hirao, Masahiro Serikawa, Bunjiro Noma, Tomoyuki Minami and 7 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Autoimmune Pancreatitis Re-Classification with Novel Type AIP-4.International journal of molecular sciences · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yumiko YamashitaDepartment of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8441, Japan.
Yasutaka IshiiDepartment of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8441, Japan. yishii@hiroshima-u.ac.jp.
Keiji HanadaDepartment of Gastroenterology, Onomichi General Hospital, Hiroshima, Japan.
Tamito SasakiDepartment of Gastroenterology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Yoshifumi FujimotoDepartment of Gastroenterology, Hiroshima General Hospital, Hiroshima, Japan.
Atsushi YamaguchiDepartment of Gastroenterology, National Hospital Organization Kure Medical Center, Chugoku Cancer Center, Hiroshima, Japan.
Ken HiraoDepartment of Internal Medicine, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
Masahiro SerikawaDepartment of Gastroenterology, Hiroshima Prefectural Hospital, Hiroshima, Japan.
Bunjiro NomaDepartment of Gastroenterology, Kure Kyosai Hospital, Hiroshima, Japan.
Tomoyuki MinamiDepartment of Gastroenterology, Hiroshima Red Cross & Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Akihito OkazakiDepartment of Gastroenterology, National Hospital Organization Higashihiroshima Medical Center, Hiroshima, Japan.
Masanobu YukutakeDepartment of Gastroenterology, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan.
Teruo MouriDepartment of Gastroenterology, Chugoku Rosai Hospital, Hiroshima, Japan.
Yumiko TatsukawaDepartment of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8441, Japan.
Shinya NakamuraDepartment of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8441, Japan.
Juri IkemotoDepartment of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8441, Japan.
Shiro OkaDepartment of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8441, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elevated serum IgG4 is a key diagnostic marker for type 1 autoimmune pancreatitis (AIP), but some patients lack IgG4 elevation, complicating diagnosis. This study investigated the clinicopathological features of AIP without elevated serum IgG4 levels. A total of 323 patients diagnosed with AIP at Hiroshima University Hospital and affiliated institutions were analyzed. Patients were categorized into IgG4-positive (≥ 135 mg/dL), IgG4-negative (< 135 mg/dL with "definite" or "probable" diagnosis), and possible (with "possible" diagnosis) groups. Comparative analysis was performed between the IgG4-positive (n = 281) and IgG4-negative (n = 20) groups. Segmental or focal narrowing of the main pancreatic duct (MPD) and retroperitoneal fibrosis were significantly more common in the IgG4-negative group (90.0% vs. 58.7%, P = 0.011; and 35.0% vs. 12.5%, P = 0.012, respectively). Although the number of pathological findings was comparable, the rate of surgical intervention was significantly higher in the IgG4-negative group (P < 0.001). No significant differences were observed in relapse rates or relapse sites between the two groups. These findings suggest that MPD narrowing and retroperitoneal fibrosis may be characteristic of AIP without elevated IgG4. Vigilant monitoring for relapse is warranted, regardless of serum IgG4 levels.

Indexed as

Autoimmune PancreatitisImmunoglobulin GAdultAgedAged, 80 and overBiomarkersFemaleHumansMaleMiddle AgedPancreatic DuctsRetroperitoneal FibrosisRetrospective StudiesBiomarkersImmunoglobulin GAutoimmune pancreatitisIgG4Lymphoplasmacytic sclerosing pancreatitisRelapseRetroperitoneal fibrosis

Identifiers

PMID40628889
PMCPMC12238352

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.